Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
"Sanofi-Aventis New Zealand Limited, Clinician",Agalsidase beta,Fabry disease (a-galactosidase deficiency) by enzyme replacment therapy,Agalsidase beta (Fabrazyme),Options for investment,Community and Hospital,Alimentary Tract and Metabolism
